Sara Alsterlind Hurvitz (Sara Hurvitz, Sara A Hurvitz)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 42

Top Topics

Quality Improvement

Epidermal Growth Factor Receptor

Top Venues

NPJ breast cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Samer Alkassis, Kasey Fitzsimmons, Sara Alsterlind Hurvitz
Pembrolizumab-induced nephrotoxicity in a patient with breast cancer. Therapeutic advances in medical oncology 16 (2024)
Javier Cortes, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Sylvaine Cartot-Cotton, Maya Stefanova-Urena, Laure Deyme, Jihane Aouni, Bernard Sebastien, Aditya Bardia
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Javier Cortes, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, David M Goldenberg, Quan Hong, Martin Olivo, Loretta M Itri, Kevin Kalinsky
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Sarina A Piha-Paul, Shane A Olwill, Erika Paige Hamilton, Anthony W Tolcher, Paula R Pohlmann, Stephen V Liu, Cornelia Wurzenberger, Laura-Carolin Hasenkamp, Eva-Maria Hansbauer, Rachna T Shroff, Sara Alsterlind Hurvitz, Anuradha Krishnamurthy, Amita Patnaik, Noah M Hahn, Raman Kumar, Manuela Duerr, Markus Zettl, Kayti Aviano, Louis Matis, Ingmar Bruns, Geoffrey Y Ku
A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Javier Cortes, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S Rugo, Patrick Neven, Dheepak Kanagavel, Patrick Cohen, Gautier Paux, Sylvaine Cartot-Cotton, Maya Stefanova-Urena, Laure Deyme, Jihane Aouni, Bernard Sebastien, Aditya Bardia
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (22) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Samer Alkassis, Kasey Fitzsimmons, Sara Alsterlind Hurvitz
Pembrolizumab-induced nephrotoxicity in a patient with breast cancer. Therapeutic advances in medical oncology 16 (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Javier Cortes, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, David M Goldenberg, Quan Hong, Martin Olivo, Loretta M Itri, Kevin Kalinsky
Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Letizia Polito, Jinjoo Shim, Sara Alsterlind Hurvitz, Chau T Dang, Adam Knott, Yolande du Toit, Eleonora Restuccia, Thibaut Sanglier, Sandra M Swain
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records. JCO oncology practice (2023)
Nicholas C Turner, A Douglas Laird, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter Andreas Fasching, Sara Alsterlind Hurvitz, Julia F Hopkins, Lee A Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M Wardley, Mark E Robson
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ breast cancer 9 (1) (2023)
Dennis J Slamon, Peter A Fasching, Sara Alsterlind Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos Henrique Barrios, Aditya Bardia, Seock-Ah Im, Denise A Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N Hortobagyi
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic advances in medical oncology 15 (2023)
Matthew P Goetz, Erika Paige Hamilton, Mario Campone, Sara Alsterlind Hurvitz, Javier Cortes, Stephen R D Johnston, Antonio Llombart, Peter A Kaufman, Masakazu Toi, Guy Jerusalem, Hillary Graham, Hong Wang, Valerie M Jansen, Lacey M Litchfield, Miguel Martin
Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Arielle J Medford, Beverly Moy, Laura M Spring, Sara Alsterlind Hurvitz, Nicholas C Turner, Aditya Bardia
Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Lisa Anne Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R Diamond, Christel Fontaine, Grace Wang, Hope S Rugo, Sara Alsterlind Hurvitz, Kevin Kalinsky, Joyce O'Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortes
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ breast cancer 8 (1) (2022)
Guy Jerusalem, Yeon Hee Park, Sara Alsterlind Hurvitz, Shanu Modi, Fabrice Andre, Ian E Krop, Xavier Gonzalez, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R Osborne, Rashmi K Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer discovery 12 (12) (2022)
Arielle S Radin, Julienne E Bower, Michael R Irwin, Arash Asher, Sara Alsterlind Hurvitz, Steve W Cole, Catherine M Crespi, Patricia A Ganz
Acute health-related quality of life outcomes and systemic inflammatory markers following contemporary breast cancer surgery. NPJ breast cancer 8 (1) (2022)
Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara Alsterlind Hurvitz, Joyce O'Shaughnessy, Javier Cortes, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, David M Goldenberg, Quan Hong, Martin Olivo, Loretta M Itri, Kevin Kalinsky
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 8 (1) (2022)
Sara Alsterlind Hurvitz
Recent progress in antibody-drug conjugate therapy for cancer. Nature cancer 3 (12) (2022)
Sara Alsterlind Hurvitz
Recent progress in antibody-drug conjugate therapy for cancer. Nature cancer 3 (12) (2022)
Sara Alsterlind Hurvitz, Thomas Bachelot, Giampaolo Bianchini, Nadia Harbeck, Sherene Loi, Yeon Hee Park, Aleix Prat, Leslie Gilham, Thomas Boulet, Nino Gochitashvili, Estefania Monturus, Chiara Lambertini, Beatrice Nyawira, Adam Knott, Eleonora Restuccia, Peter Schmid
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future oncology (London, England) (2022)
Sara Alsterlind Hurvitz
Recent progress in antibody-drug conjugate therapy for cancer. Nature cancer 3 (12) (2022)
Sara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, Michael F Press, Mark D Pegram, John P Crown, Peter Andreas Fasching, Bent Ejlertsen, Eric H Yang, John A Glaspy, Dennis J Slamon
A careful reassessment of anthracycline use in curable breast cancer. NPJ breast cancer 7 (1) (2021)
Sara Alsterlind Hurvitz
Finding the Sweet Spot in the Management of Early HER2+ Breast Cancer. JCO oncology practice 17 (6) (2021)
Sara Alsterlind Hurvitz, Cristina Saura, Mafalda Oliveira, Maureen E Trudeau, Beverly Moy, Suzette Delaloge, William Gradishar, Sung-Bae Kim, Barbara Haley, Larisa Ryvo, Ming-Shen Dai, Vladimir Milovanov, Jesús Alarcón, Sujith Kalmadi, Eduardo Cronemberger, Cristiano Souza, Luciana Landeiro, Ron Bose, Judith Bebchuk, Fairooz Kabbinavar, Richard Bryce, Kiana Keyvanjah, Adam M Brufsky
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. The oncologist 26 (8) (2021)
Hannah Van Belle, Sara Alsterlind Hurvitz, Peter Jeffrey Gilbar, Hans P M W Wildiers
Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. Breast cancer research and treatment 190 (3) (2021)
Sarah F D'Ambruoso, John A Glaspy, Sara Alsterlind Hurvitz, Neil S Wenger, Christopher Pietras, Kauser Ahmed, Alexandra Drakaki, Jonathan Wade Goldman, Sidharth Anand, Wendy M Simon, Jennie Kung, Anne Coscarelli, Lee S Rosen, Parvin F Peddi, Deborah J L Wong, Katherine Santos, Peter Phung, Daniel Karlin, Anne M Walling
Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO oncology practice (2021)
Caspian Oliai, Michael L Douek, Caelainn Rhoane, Abhishek Bhutada, Phillip S Ge, Bruce A Runyon, Xiaoyan Wang, Sara Alsterlind Hurvitz
Clinical features of pseudocirrhosis in metastatic breast cancer. Breast cancer research and treatment 177 (2) (2019)
Sara Alsterlind Hurvitz, Anthony Gonçalves, Hope S Rugo, Kyung-Hun Lee, Louis Fehrenbacher, Lida A Mina, Sami Diab, Joanne L Blum, Jayeta Chakrabarti, Mohamed Elmeliegy, Liza DeAnnuntis, Eric Gauthier, Akos Czibere, Iulia Cristina Tudor, Ruben G W Quek, Jennifer K Litton, Johannes Ettl
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. The oncologist 25 (3) (2019)
Hope S Rugo, Johannes Ettl, Sara Alsterlind Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Lida A Mina, Sami Diab, Natasha E Woodward, Rinat Yerushalmi, Annabel Goodwin, Joanne L Blum, Miguel Martin, Ruben G W Quek, Iulia Cristina Tudor, Helen Bhattacharyya, Eric Gauthier, Jennifer K Litton, Wolfgang Eiermann
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI cancer spectrum 4 (1) (2019)
Sara Alsterlind Hurvitz, Anthony Gonçalves, Hope S Rugo, Kyung-Hun Lee, Louis Fehrenbacher, Lida A Mina, Sami Diab, Joanne L Blum, Jayeta Chakrabarti, Mohamed Elmeliegy, Liza DeAnnuntis, Eric Gauthier, Akos Czibere, Iulia Cristina Tudor, Ruben G W Quek, Jennifer K Litton, Johannes Ettl
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. The oncologist (2019)